Mark Mullen, MD

Combining cognitive behavioral therapy with medication enhances ADHD treatment in adults, showing significant benefits within 3 months.

Antidepressant treatment for late-life depression enhances cognitive functions like memory and learning, linking symptom relief to cognitive improvement.

Social media use among older adults shows potential benefits for reducing loneliness and improving psychosocial well-being, though results vary across studies.

Research reveals that IV haloperidol and ziprasidone are safe for treating delirium in patients that are critically ill, showing minimal impact on QTc intervals.

New research reveals that discontinuing long-term benzodiazepine therapy may increase risks of mortality and other adverse outcomes, challenging common assumptions.

Ketamine or ECT? A new study reveals which works best for severe depression—depending on the patient and setting.

Recent research demonstrated that xanomeline-trospium is more efficacious than placebo in treating positive and negative psychotic symptoms in adults with schizophrenia.

Clinicians should consider rTMS as an intervention to alleviate OCD symptoms, especially in those who have failed other treatments or those with comorbid depression.

Patients with personality disorders would benefit from therapy regardless of modality, duration, or intensity.

A systematic review and meta-analysis showed moderate-quality evidence supporting lithium’s ability to lower mortality rates.

A new study shows that rTMS has moderate therapeutic effects on OCD severity.

Evidence indicates that children and adolescents with ADHD have a more than 4-fold increased risk of schizophrenia spectrum and other psychotic disorders in adulthood compared with the general population.

This randomized, placebo-controlled, phase 3 clinical trial showed that a 14-day treatment course of oral zuranolone 50 mg/day in MDD led to significantly greater improvements in depressive symptoms when compared with placebo.

A study assessed the associations between the use of ADHD medications and CVD over the course of 14 years. Here's what the investigators found.

Recent research investigated the benefits and risks of augmentation compared with switching strategies for TRD in older adults.

Two phase 3 trials were conducted to assess the clinical and biological effects as well as the safety of gantenerumab in individuals with mild cognitive impairment or mild dementia due to AD. Here's what you need to know.

How efficacious is brexpiprazole as a treatment for agitation associated with Alzheimer disease?